Overactive Bladder News Archive

Nocturia Symptoms Eased With Novel Drug Combo

Nocturia Symptoms Eased With Novel Drug Combo

In a phase 2 trial, treatment with an acetaminophen-ibuprofen combination was associated with a significant reduction in nocturnal voids and improved quality of life compared with placebo.

Nocturia in BPH Patients Safely Treated with Silodosin

Nocturia in BPH Patients Safely Treated with Silodosin

In a study, 8 mg of silodosin daily for 12 weeks was associated with a significant reduction in nocturia episodes.

Nocturia Diagnosis, Management Strategies Offered

Nocturia Diagnosis, Management Strategies Offered

A recent paper provides 8 questions to ask patients to elicit information that enables targeted treatment of nocturia.

Low-Dose Melatonin Found Not To Ease Nocturia in MS

Low-Dose Melatonin Found Not To Ease Nocturia in MS

Small study found that 2 mg of melatonin taken at bedtime did not significantly decrease the mean number of nocturia episodes vs placebo.

New LUTS Classification for Women Proposed

New LUTS Classification for Women Proposed

Women presenting with lower urinary tract symptoms cluster into 4 distinct symptom groups, according to a recent study.

Bladder Hydrodistention May Ease Nocturia in Interstitial Cystitis

Bladder Hydrodistention May Ease Nocturia in Interstitial Cystitis

Bladder hydrodistention with fulguration of Hunner lesions reduced nocturia in IC patients with or without nocturnal polyuria.

OAB, Nocturia Linked With Higher Fall Risk

OAB, Nocturia Linked With Higher Fall Risk

Treatment appeared to reduce fall risk among older adults.

Multiple Risk Factors Linked With Nocturia

Multiple Risk Factors Linked With Nocturia

Study confirms associations between nocturia and older age, female sex, overactive bladder, and diabetes.

Nocturia May Increase Death Risk

Nocturia May Increase Death Risk

Men experiencing 3 or more nocturia episodes per night had a 43% increased mortality risk in adjusted analyses.

Nocturia Evaluation, Treatment Fall Short

Nocturia Evaluation, Treatment Fall Short

In a study, only 5% of nocturia and nocturnal polyuria were prescribed oral desmopressin.

Nocturia More Bothersome Than Daytime LUTS

Nocturia More Bothersome Than Daytime LUTS

Clinicians tend to focus on the number of voids, but patients worry more about interrupted sleep.

Hypoxia Not Linked With Nocturia

Hypoxia Not Linked With Nocturia

Rather intermittent oxygen desaturation was associated with a 3% greater likelihood of nocturia.

FDA Approves Mirabegron Solifenacin Combo for OAB

FDA Approves Mirabegron Solifenacin Combo for OAB

In clinical trials, the combination of Myrbetriq + solifenacin succinate was associated with greater improvements in the number of incontinence episodes per 24 hours (primary endpoint), the number of micturations per 24 hours (primary endpoint), and the volume voided per micturation (secondary endpoint) compared to placebo or to individual active components.

Predictors of Pediatric OAB Healing Time Identified

Predictors of Pediatric OAB Healing Time Identified

Thicker bladder wall and a tower-shaped curve on uroflowmetry are associated with shorter healing periods among pediatric patients with overactive bladder.

Nasal Spray for Nocturia Is Safe, Effective

Nasal Spray for Nocturia Is Safe, Effective

More patients taking desmopressin decreased their nightly voiding episodes by half or more.

Urodynamics Influence OAB Treatment Decisions

Urodynamics Influence OAB Treatment Decisions

Clinicians' choice of treatment highly correlated with a diagnosis based on urodynamic studies.

Nonpharmacologic Therapy Ups Sleep Quality in Women With Nocturia

Nonpharmacologic Therapy Ups Sleep Quality in Women With Nocturia

At least half of women using tibial nerve stimulation or pelvic floor muscle training experienced fewer night awakenings, according to a new study.

Nocturia in Men Linked to Metabolic Syndrome, Smoking

Nocturia in Men Linked to Metabolic Syndrome, Smoking

Metabolic syndrome and smoking are associated with 2.5- and 1.7-fold increased odds of moderate or severe nocturia in men with BPH/LUTS.

Sleep Disorders in Men Associated With Nocturia

Sleep Disorders in Men Associated With Nocturia

In a study, men with sleep disorders were 23% and 27% more likely to report nocturia and daytime LUTS than men without sleep disorders.

Poor Sleep Quality Common in Women With Urgency Incontinence

Poor Sleep Quality Common in Women With Urgency Incontinence

At baseline, women reported an average of 3.9 urgency incontinence episodes per day and 1.3 episodes of nocturia per night.

Nocturia May Contribute to Sleep Problems in ADT Recipients

Nocturia May Contribute to Sleep Problems in ADT Recipients

In a 12-month study, men with prostate cancer treated with ADT reported more nocturia episodes than men with prostate cancer treated with prostatectomy alone and men with no history of cancer.

Methylene Blue Improves Onabotulinum Toxin A Injection Technique

Methylene Blue Improves Onabotulinum Toxin A Injection Technique

Methylene blue aids observation of the procedure and assessment of drug distribution.

Antimuscarinic Therapy for OAB Linked to Depression in Women

Antimuscarinic Therapy for OAB Linked to Depression in Women

Clinicians should be alert to the relationship between antimuscarinics usage and depressive disorder in OAB women and provide appropriate instructions for these patients.

Botulinum Toxin Evaluated for Overactive Bladder

Botulinum Toxin Evaluated for Overactive Bladder

Onabotulinumtoxin A successfully reduced urinary frequency and urgency, but not urgency urinary incontinence episodes.

Oxybutynin Overprescribed for Overactive Bladder in Elderly

Oxybutynin Overprescribed for Overactive Bladder in Elderly

Pharmacologic properties of oxybutynin may cause significant cognitive side effects in elderly persons.

OAB Drug Mirabegron Shows Superior Patient Adherence

OAB Drug Mirabegron Shows Superior Patient Adherence

Treatment discontinuation rate is lower than that of traditional antimuscarinics, study finds.

Long-Term BoNT-A Therapy Compliance Low Among Men

Long-Term BoNT-A Therapy Compliance Low Among Men

Only a quarter of men receiving injections of BoNT-A comply with the treatment long-term.

OAB Sacral Neuromodulation Causes Few Serious Adverse Events

OAB Sacral Neuromodulation Causes Few Serious Adverse Events

Prospective study reveals a 1-year surgical intervention rate of 13%.

OnabotulinumtoxinA Provides Lasting Benefit in Overactive Bladder

OnabotulinumtoxinA Provides Lasting Benefit in Overactive Bladder

Consistent mean reductions in urinary incontinence; durable improvements in quality of life.

Post-RP Radiation Therapy May Raise OAB Risk

Post-RP Radiation Therapy May Raise OAB Risk

De novo OAB — defined as urgency with or without frequency and nocturia — developed in some patients.

Surgical Revision Rate 4% for Mesh-Based Prolapse Surgery

Surgical Revision Rate 4% for Mesh-Based Prolapse Surgery

Reoperation rate for transvaginal mesh prolapse surgery is 4%.

Patients on Psychiatric Meds Report More Severe OAB Symptoms

Patients on Psychiatric Meds Report More Severe OAB Symptoms

These same patients, however, had less intense detrusor overactivity, urodynamic evaluation revealed.

Specialists More Likely to Prescribe Newer OAB Drugs Initially

Specialists More Likely to Prescribe Newer OAB Drugs Initially

Urologists and gynecologists are 49% and 30% more likely than primary care doctors to prescribe second-generation agents.

Potential Medication Misuse Common With OAB

Potential Medication Misuse Common With OAB

Potentially inappropriate medication use is prevalent in older adults undergoing antimuscarinic treatment for overactive bladder.

Mirabegron Found to Relieve Refractory OAB in Children

Mirabegron Found to Relieve Refractory OAB in Children

Patients' median bladder capacity improved from 150 to 200 mL and continence improved in nearly 90% of patients.

Overactive Bladder Risk Higher in Women Who Smoke

Overactive Bladder Risk Higher in Women Who Smoke

Researchers also find a significant association between smoking and secondary nocturnal enuresis.

Botox Effectively Treats New OAB After Incontinence Surgery

Botox Effectively Treats New OAB After Incontinence Surgery

A high cure rate was observed in women with de novo OAB symptoms following transobturator tape surgery.

Combo Superior for Overactive Bladder in BPH Patients

Combo Superior for Overactive Bladder in BPH Patients

Symptom improvement was greater in patients receiving tamsulosin plus darifenacin compared with tamsulosin monotherapy.

Pelvic Floor Stimulation Improves OAB in Perimenopausal Women

Pelvic Floor Stimulation Improves OAB in Perimenopausal Women

Adding vaginal estrogen may sustain the effects.

Two-Drug Combo Effective for Severe OAB in Elderly

Two-Drug Combo Effective for Severe OAB in Elderly

Among seniors with severe overactive bladder, a combination of solifenacin and mirabegron decreased incontinence by an average 3.5 episodes a day.

Sacral Neuromodulation Testing Increasing

Sacral Neuromodulation Testing Increasing

The number of neuromodulation test procedures performed per physician has increased.

Overactive Bladder Medications Only Slightly Beneficial

Overactive Bladder Medications Only Slightly Beneficial

Small reductions in urge incontinence episodes, voids per day with daily dose of medications.

OAB Drugs Prescribed Less Frequently to Men

OAB Drugs Prescribed Less Frequently to Men

A study found that 33.8% of women received anticholinergics compared with 19.4% of men.

Overactive Bladder Increases Falling Risk in the Elderly

Overactive Bladder Increases Falling Risk in the Elderly

OAB treatment is associated with a decreased risk of falls, study finds.

OAB, SUI Worse After Vaginal Birth

OAB, SUI Worse After Vaginal Birth

Regardless of delivery type, obesity ups the risk of more severe urinary symptoms, study shows.

Overactive Bladder Found to Raise Nocturia Risk

Overactive Bladder Found to Raise Nocturia Risk

In a study, severe nocturia predicted increased mortality risk.

Combined High-Dosage Drugs Shown to Ease Resistant OAB

Elderly patients with OAB may benefit from combined high-dosage antimuscarinics.

Repeat BTXA Injections Okay for Non-Neurogenic OAB

Repeat injections of onabotulinumtoxinA (BTXA) appear to benefit patients with non-neurogenic overactive bladder.

Stubborn Overactive Bladder Responds to Sacral Neuromodulation

Improvements in efficacy and quality of life last at least six months, study finds.

Nocturia Bidirectionally Linked with Depression

Nocturia Bidirectionally Linked with Depression

Depression risk greater for men with nocturia than for women with nocturia.

Desmopressin Effective for Nocturia in Women

Desmopressin Effective for Nocturia in Women

Two studies show significant reduction in number of nocturnal voids for women.

Percutaneous Tibial Nerve Stimulation Has Lasting Benefit

Percutaneous Tibial Nerve Stimulation Has Lasting Benefit

In most responders, overactive bladder symptom improvement sustained to three years.

FDA: Phony Botox Purveyors Targeting U.S. Practices

FDA: Phony Botox Purveyors Targeting U.S. Practices

Products advertised through fax; not FDA approved.

FDA Approves 1st OTC Drug for Women With Overactive Bladder

FDA Approves 1st OTC Drug for Women With Overactive Bladder

Oxytrol is intended for use by those 18 and older.

Increasing Solifenacin Dose Can Improve Outcomes in Severe OAB

Increasing the daily dose from 5 to 10 mg resulted in reductions in mean total urgency score and mean micturition frequency.

FDA Approves Botox for Overactive Bladder

The FDA has approved onabotulinumtoxinA (Botox) as a treatment for overactive bladder (OAB) in adults who are inadequately managed with anticholinergic medications.

Overactive Bladder Risk Higher in Diabetics

Patients with type 2 diabetes are twice as likely as nondiabetics to suffer from the condition.

New Overactive Bladder Drug Approved

Mirabegron is the first oral OAB drug with a distinct mechanism of action to be approved in three decades.

Fesoterodine Relieves Nocturnal Urgency in OAB Patients

Flexible-dose fesoterodine is superior to placebo in decreasing the number of nocturnal urgency episodes and nocturnal micturitions in patients with overactive bladder (OAB), researchers reported at the American Urological Association 2012 annual meeting.

OAB Patients Most Bothered by Urgency

Patients with overactive bladder (OAB) say they are most bothered by symptoms of urinary urgency either as a primary complaint or as a driving symptom for frequency, according to a pilot study presented at the American Urological Association 2012 annual meeting.

BoNTA Safe, Effective for Diabetic OAB Patients

Diabetes has no influence on intravesical botulinum toxin type A (BoNTA) injection in overactive bladder (OAB) patients, researchers reported at the American Urological Association 2012 annual meeting.

Oxybutynin Gel Eases Urinary Incontinence

A new oxybutynin gel (OTG) with propylene glycol to aid transdermal delivery, which dispensed via a pump, is effective for treating urgency and mixed urinary incontinence (UI), according to the findings of a phase 3 study presented at the American Urological Association 2012 annual meeting.

OAB Sufferers Less Physically Active

Men and women with overactive bladder (OAB) are significantly less likely to achieve recommended physical activity levels than those with no or minimal symptoms (NMS) of OAB, according to a poster presentation at the American Urological Association 2012 annual meeting.

Transdermal Gel for Overactive Bladder Launched

Watson Pharmaceuticals of Parsippany, N.J., and Antares Pharma. Inc. of Ewing, NJ, have announced the launch of Gelnique (oxybutynin), a transdermal gel for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency.

Novel Drug for Overactive Bladder Works Even If Antimuscarinics Do Not

PARIS—Mirabegron, an experimental drug for overactive bladder (OAB), can effectively treat the condition in patients whether or not they failed previous antimuscarinic therapy, according to findings presented at the 27th Annual Congress of the European Association of Urology.

Repeated Toxin Injections Safe and Effective for Refractory Overactive Bladder

Repeated injections of botulinum toxin type A (BoNTA) are safe and effective for the medium-term management of refractory overactive bladder (OAB) and idiopathic detrusor overactivity (IDO), according to British investigators.

Overactive Bladder Linked to Metabolic Syndrome in Women

Metabolic syndrome is associated with overactive bladder (OAB) in women, according to researchers.

Botulinum Toxin Effective in OAB Patients without Detrusor Overactivity

GLASGOW—Intravesical botulinum toxin may be an effective treatment for overactive bladder (OAB) without detrusor overactivity (DOA) on urodynamic assessment, researchers reported at the International Continence Society annual meeting.

Approval Sought for New Overactive Bladder Drug

If cleared by the FDA, mirabegron would be the first oral treatment with a new mechanism of action for OAB in almost 30 years.

Antibiotics May Improve Treatment of Overactive Bladder

GLASGOW—Antibiotics may be a useful adjunctive treatment for overactive bladder (OAB), according to British researchers.

Trigonal Injections of Botulinum Toxin Improve OAB Outcomes

WASHINGTON, D.C.—Trigonal intradetrusor injections of botulinum toxin-A (BTX-A) results in greater reduction in overactive bladder (OAB) symptoms compared with trigone-sparing BTX-A injections, Irish investigators reported at the American Urological Association 2011 annual meeting.

Overactive Bladder Often Associated with Pelvic Organ Prolapse

WASHINGTON, D.C.—Posterior compartment pelvic organ prolapse (POP) in women is often associated with overactive bladder (OAB), and POP surgery may help to decrease OAB symptoms as well as detrusor overactive (DO), according to study findings presented at the American Urological Association 2011 annual meeting.

Surrogate Markers May Identify Age-Associated Biochemical Changes in OAB patients

WASHINGTON, D.C.—Urinary nerve growth factor (NGF) and MCP-1 may be surrogate markers for monitoring age-associated biochemical changes in patients with overactive bladder (OAB), according to data presented at the American Urological Association 2011 annual meeting.

'OAB-Dry' May Need to be Reassessed

WASHINGTON, D.C.—Questionnaires used to diagnose patients with overactive bladder (OAB) may identify anyone with polyuria, bladder hypersensitivity, and even OAB-wet with rare leakage episodes as OAB-dry, investigators reported at the American Urological Association 2011 annual meeting.

Overactive Bladder Found in One Fifth of Type 2 Diabetics

WASHINGTON, D.C—Japanese researchers found that more than one fifth of patients with type 2 diabetes receiving care at a dedicated diabetes center have overactive bladder (OAB).

Nocturia Is the Most Bothersome OAB Symptom in POTS Patients

WASHINGTON, D.C.—Nocturia is the most common overactive bladder (OAB) symptom affecting health-related quality of life (HRQL) in patients with postural tachycardia syndrome (POTS), investigators reported at the American Urological Association 2011 annual meeting.

Parkinson's Severity Associated with OAB Symptoms

WASHINGTON, D.C.—Overactive bladder (OAB) symptoms are common in patients with Parkinson's disease regardless of age and gender, and the severity of Parkinson's symptoms correlates with OAB symptoms, according to a study presented at the American Urological Association 2011 annual meeting.

OAB Symptoms Linked to Elevated Serum Leptin

WASHINGTON, D.C.—Elevation of serum leptin and a decrease in monocyte chemotactic protein-1 (MCP-1) levels are associated with overactive bladder (OAB) symptoms, according to new data presented at the American Urological Association 2011 annual meeting.

Sacral Neuromodulation Found Effective and Well-Tolerated

WASHINGTON, D.C.—Sacral neuromodulation with InterStim Therapy is safe and well tolerated as a treatment for patients with overactive bladder and those with urinary retention, French investigators reported at the American Urological Association 2011 annual meeting.

Adverse Events Common After Botulinum Toxin Injections

WASHINGTON, D.C.—Adverse events (AEs) after intravesical botulinum toxin type A for idiopathic detrusor overactivity (IDO) are encountered frequently, according to a new study presented at the American Urological Association 2011 annual meeting.

Botulinum Toxin Effective Long Term for Severe OAB

WASHINGTON, D.C.—Detrusor botulinum toxin type A injections are a safe and effective treatment long-term for patients with severe overactive bladder (OAB), Swiss researchers reported at the American Urological Association 2011 annual meeting.

OAB Affects Work Productivity

WASHINGTON, D.C.—Men and women who suffer from overactive bladder (OAB) report significantly greater levels of work limitations compared with those without urinary symptoms, according to a new study presented at the American Urological Association 2011 annual meeting.

Remission of Urologic Symptoms Not Uncommon

WASHINGTON, D.C.—The natural history of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) may involve as much remission as progression, according to a new longitudinal study presented at the American Urological Association 2011 annual meeting.

Overactive Bladder Highly Prevalent, Study Finds

WASHINGTON, D.C.—Overactive bladder (OAB) is highly prevalent in both women and men and the prevalence varies by race and ethnicity, according to study findings presented at the American Urological Association 2011 annual meeting.

BoNT-A Efficacy for Idiopathic Detrusor Overactivity Confirmed

VIENNA—Findings from a large randomized trial confirm the effectiveness of botulinum toxin type A (BoNT-A) for refractory idiopathic detrusor overactivity (IDO) in women.

Healthy Habits May Improve Urinary, Sexual Function

SAN FRANCISCO—Healthy lifestyle choices, such as not smoking and exercising regularly, may significantly impact urinary and sexual function, two studies suggest.

Fesoterodine for OAB Shows Efficacy at One Week

In a recent study, fesoterodine showed rapid onset of efficacy at one week in patients with overactive bladder (OAB) who were previously treated with tolterodine and dissatisfied with that drug.

Potential Gene Biomarkers for OAB Identified

TORONTO—An analysis of gene-expression patterns in women with overactive bladder (OAB) may point the way to possible new biomarkers for the condition.

Overactive Bladder Linked to Inflammation

SAN FRANCISCO—Increasing levels of C-reactive protein (CRP) are associated with increasing odds of overactive bladder (OAB), according to a population-based study of men and women.

PTNS Safe and Effective for Overactive Bladder

Percutaneous tibial nerve stimulation (PTNS) is safe and effective for treating overactive bladder (OAB) symptoms, a recent study shows.

Study: Most OAB Cases Go Untreated

The associated cost is a potential reason for undertreatment.

Study: Most Overactive Bladder Cases Go Untreated

Only 24.4% of patients aged 45 years and older take drugs for the condition, according to researchers.

PTNS Provides Sustained Overactive Bladder Relief

Study findings at 12 months showed prolonged significant improvements in objective urinary parameters.

OAB Meds Not Equal When It Comes To Adverse Effects

Solifenacin-treated patients experienced less dry mouth than those taking oxybutynin immediate release.

Nerve Stimulation An Overactive Bladder Option

Percutaneous tibial nerve stimulation may be considered an alternative treatment for overactive bladder (OAB), researchers reported in the Journal of Urology (2009;182:1055-1061).

Patent Issued for OAB Neuromodulation System

Uroplasty, Inc., a medical device company with headquarters in Minnetonka, Minn., has received a patent for its Urgent PC Neuromodulation System and stimulation methods for treating overactive bladder (OAB).

Novel Botox Therapy May Work for Idiopathic Refractory OAB

Researchers have reported encouraging results from a small study examining intravesical instillation of a botulinum toxin/dimethyl sulfoxide (DMSO) solution as a treatment for refractory idiopathic overactive bladder (OAB).

First and Only Topical Gel for Overactive Bladder Cleared

Watson Pharmaceuticals, Corona, Calif., has received approval for Gelnique (oxybutynin chloride) Gel 10%, the first and only topical gel for the treatment of overactive bladder (OAB).

Sacral Neuromodulation Can Ease Refractory Overactive Bladder in the Elderly

Sacral Neuromodulation Can Ease Refractory Overactive Bladder in the Elderly

The procedure is ideal in this population because it is minimally invasive and highly efficacious

Overactive Bladder Findings in Diabetic Women

Increased bladder sensation and detrusor overactivity are the most frequent urodynamic findings of overactive bladder (OAB) in women with diabetes, researchers in Taiwan reported in Neurourology and Urodynamics (2009; published online ahead of print).

Sign Up for Free e-newsletters